Skip to main content
    T

    Thermo Fisher Scientific Inc (TMO)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $687.29
    -4.04 (-0.58%)

    Market Cap: $256.15B

    Last updated: Nov 17, 2026 at 4:32 PM ET

    Thermo Fisher Scientific Inc (TMO) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Thermo Fisher Scientific (TMO) has a market cap of $256.15B and an enterprise value of $292.06B. Its share count is down 2.12% from a year earlier.

    Total Valuation

    Enterprise value is 14.02% above the market cap, as debt exceeds cash.

    Market Cap$256.15B
    Enterprise Value$292.06B
    Latest price (Nov 17, 2026)$687.29

    Key Dates

    The next earnings report is expected on Jan 27, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Dec 15, 2026.

    Next Earnings DateJan 27, 2027 (expected)
    Last Earnings DateOct 21, 2026
    Next Ex-Dividend DateDec 15, 2026
    Next Payment DateJan 15, 2027
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.27% in the quarter ended Sep 30, 2026 and shrank 1.58% a year over 2 years.

    Shares Outstanding370.00M
    Shares Change (YoY)-2.12%
    Shares Change (QoQ)-0.27%
    Share Count Growth (2Y CAGR)-1.58%

    Valuation Ratios

    Sales and book value multiples are 5.4x and 4.6x. Its year-end P/E ranged from 17.1x to 26.6x from 2016 to 2025.

    P/E Ratio27.8x
    Forward P/E26.9x
    P/S Ratio5.4x
    Forward P/S5.3x
    P/B Ratio4.6x
    P/FCF Ratio33.5x
    P/OCF Ratio27.5x
    PEG Ratio2.7

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 25.1x EBITDA and 38.2x free cash flow.

    EV / Earnings41.2x
    EV / Sales6.2x
    EV / EBITDA25.1x
    EV / EBIT34.5x
    EV / FCF38.2x

    Price Statistics

    The stock is up 18.97% over 52 weeks and trades 2.00% above its 50-day average.

    Beta (1Y)0.69
    52-Week Change+18.97%
    1-Month Change+1.16%
    3-Month Change+12.10%
    6-Month Change+53.74%
    5-Year Change+10.10%
    10-Year Change+374.05%
    Total Return (1Y)+19.29%
    Total Return (3Y CAGR)+14.05%
    Total Return (5Y CAGR)+1.75%
    Return vs SPY (1Y)+7.97%
    Max Drawdown (1Y)-31.50%
    Max Drawdown (3Y)-37.27%
    Sharpe Ratio (1Y)0.60
    Correlation with SPY (1Y)0.32
    50-Day Average$673.82
    200-Day Average$555.98
    52-Week Range$434.50 to $727.56
    RSI (14 Days)49.1
    Average Volume (20 Days)2.11M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.81x current liabilities, and total debt is 0.76x shareholder equity.

    Current Ratio1.81x
    Quick Ratio1.41x
    Debt / Equity0.76x
    Debt / EBITDA3.58x
    Debt / FCF5.45x
    Interest Coverage5.45x

    Returns and Efficiency

    Return on invested capital is 7.97% over the last 12 months, against a 5-year average of 8.86%.

    Return on Equity (ROE)12.96%
    Return on Assets (ROA)6.21%
    Return on Invested Capital (ROIC)7.97%
    Return on Capital Employed (ROCE)8.45%
    ROE (5Y Average)14.58%
    ROA (5Y Average)6.78%
    ROIC (5Y Average)8.86%
    Asset Turnover0.44x
    Inventory Turnover4.95x
    Receivables Turnover4.96x
    Cash Conversion Cycle106 days

    Taxes

    Income tax took 9.39% of pretax income over the last 12 months.

    Income Tax (TTM)$742.00M
    Effective Tax Rate9.39%

    Scores

    TMO has an Altman Z-Score of 4.13, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score4.13
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $47.35B over the last 12 months is up 8.27% from the 12 months before.

    Revenue$47.35B
    Revenue Growth (YoY)+8.27%
    Gross Profit$19.45B
    Operating Income$8.47B
    Pretax Income$7.90B
    Net Income$7.09B
    EBITDA$11.56B
    EBIT$8.46B
    Reported EPS (TTM)$24.72

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 47.94% of the $114.23B in total assets.

    Cash and Equivalents$5.46B
    Total Debt$41.37B
    Net Debt$35.91B
    Net Debt Per Share$97.05
    Working Capital$11.45B
    Shareholder Equity$54.76B
    Book Value Per Share$148.01
    Tangible Book Value-$17.58B
    Total Assets$114.23B
    Total Liabilities$59.34B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.73B of capital spending, operating cash flow left $7.60B of free cash flow.

    Operating Cash Flow$9.32B
    Capital Expenditures$1.73B
    Free Cash Flow$7.60B
    FCF Per Share$20.54
    Depreciation and Amortization$3.11B
    Dividends Paid$673.00M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 17.88%, against a 5-year average of 18.95%.

    Gross Margin41.08%
    Operating Margin17.88%
    Pretax Margin16.68%
    Net Margin14.98%
    EBITDA Margin24.42%
    EBIT Margin17.86%
    FCF Margin16.04%
    Gross Margin (5Y Average)42.89%
    Operating Margin (5Y Average)18.95%
    Net Margin (5Y Average)15.79%

    Growth

    Revenue fell 0.27% a year over 3 years, and EPS 0.53% a year.

    Revenue Growth (3Y CAGR)-0.27%
    Revenue Growth (5Y CAGR)+6.70%
    EPS Growth (3Y CAGR)-0.53%
    EPS Growth (5Y CAGR)+3.19%
    FCF Growth (3Y CAGR)-3.07%
    FCF Growth (5Y CAGR)-1.58%
    Operating Income Growth (3Y CAGR)-2.64%
    Book Value Per Share Growth (2Y CAGR)+8.45%

    Revenue and profit by year

    Dividends and Yields

    TMO pays out 7.30% of earnings as dividends.

    Dividend Per Share (Annual)$1.88
    Dividend Yield0.27%
    Payment ScheduleQuarterly
    Dividend Growth (3Y CAGR)+12.75%
    Dividend Growth (5Y CAGR)+14.34%
    Payout Ratio7.30%
    FCF Payout Ratio8.86%
    Earnings Yield3.60%
    FCF Yield2.99%
    Buyback Yield1.59%
    Shareholder Yield1.85%

    Full dividend history

    Peer Position

    Against 11 similar companies, TMO has the 7th highest P/E.

    P/E Ratio27.8x vs 28.4x median
    P/S Ratio5.4x vs 6.4x median
    ROIC7.97% vs 8.31% median
    Revenue Growth (Trailing 4 Quarters, YoY)+8.27% vs +6.71% median
    Dividend Yield0.27% vs 0.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 6.50% and EPS growth at 10.22% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+6.50%
    EPS Growth Forecast (2Y CAGR)+10.22%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TMO

    What is TMO's market cap?

    Thermo Fisher Scientific has a market cap of $256.15B. Its enterprise value, which adds debt and subtracts cash, is $292.06B.

    What is TMO's P/E ratio?

    Thermo Fisher Scientific has a trailing P/E ratio of 27.8x and a forward P/E of 26.9x.

    How many shares of TMO are outstanding?

    Thermo Fisher Scientific has 370.00M shares outstanding. The count is down 2.12% from a year earlier.

    Does TMO pay a dividend?

    Yes. Thermo Fisher Scientific pays $1.88 a share a year, a dividend yield of 0.27%.

    How much debt does TMO have?

    Thermo Fisher Scientific has $41.37B of total debt and $5.46B of cash and equivalents, a net debt position of $35.91B.